Physician profile
Kenneth David Chinsky
NPI 1508833112
$34,549.79
in general payments reported to CMS, 2019-2025
23 companies · $23K in 2025
The $23K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,373 · 2020: $2,049 · 2021: $11.56 · 2022: $63.07 · 2023: $280 · 2024: $881 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,228 · Food and Beverage: $1,464 · Consulting Fee: $1,000 · Travel and Lodging: $844 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $13,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,228.00 |
| Food and Beverage | $1,463.75 |
| Consulting Fee | $1,000.00 |
| Travel and Lodging | $843.91 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $13,957.87 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,094.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $8,520.62 | 2019-2025 | Nucala |
| Pfizer INC. | $820.06 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $325.00 | 2020-2023 | |
| Gilead Sciences, INC. | $145.72 | 2019-2024 | Veklury |
| Jazz Pharmaceuticals INC. | $124.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $119.61 | 2019-2025 | Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $119.49 | 2019-2025 | Dupixent |
| Pulmonx Corporation | $63.07 | 2022 | |
| Harmony Biosciences LLC | $38.46 | 2025 | |
| Janssen Pharmaceuticals, INC | $33.60 | 2019-2020 | |
| Insmed, INC. | $27.27 | 2020-2025 | Brinsupri |
| Idorsia Pharmaceuticals US INC | $20.87 | 2025 | Quviviq |
| Ethicon INC. | $19.88 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $18.75 | 2025 | Horizant |
| Viatris Specialty LLC | $17.53 | 2025 | Yupelri |
| Grifols USA, LLC | $15.61 | 2025 | Prolastin-C Liquid |
| Advanced Respiratory, INC | $14.94 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2025 | Glassia |
| Mylan Specialty L.P. | $12.93 | 2019 | |
| Circassia INC. | $12.55 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Chinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.